Mason & Associates (California)’s AbbVie ABBV Stock Holding History

Mason & Associates (California)’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$833K	Sell	3,310 -111	-3%	-$23.9K	0.13%	85
2026 Q1	$729K	Sell	3,421 -61	-2%	-$13.5K	0.14%	87
2025 Q4	$796K	Buy	3,482 +67	+2%	+$15.3K	0.15%	75
2025 Q3	$791K	Buy	3,415 +1	+0%	+$204	0.16%	59
2025 Q2	$634K	Buy	3,414 +439	+15%	+$81.6K	0.15%	67
2025 Q1	$623K	Sell	2,975 -1,531	-34%	-$298K	0.15%	65
2024 Q4	$801K	Buy	4,506 +1,499	+50%	+$276K	0.19%	58
2024 Q3	$594K	Sell	3,007 -354	-11%	-$66.1K	0.15%	68
2024 Q2	$576K	Sell	3,361 -38	-1%	-$6.29K	0.15%	61
2024 Q1	$619K	Buy	3,399 +1	+0%	+$172	0.17%	56
2023 Q4	$527K	Buy	3,398 +139	+4%	+$20.3K	0.15%	53
2023 Q3	$486K	Buy	3,259 +1	+0%	+$147	0.16%	49
2023 Q2	$439K	Buy	3,258 +79	+2%	+$11.6K	0.13%	55
2023 Q1	$507K	Buy	3,179 +2	+0.1%	+$306	0.16%	50
2022 Q4	$513K	Sell	3,177 -227	-7%	-$34.8K	0.16%	47
2022 Q3	$457K	Buy	3,404 +2	+0.1%	+$287	0.16%	49
2022 Q2	$521K	Sell	3,402 -160	-4%	-$24.4K	0.18%	50
2022 Q1	$577K	Buy	+3,562	New	+$517K	0.18%	60

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Mason & Associates (California)'s ABBV Position: Q2 2026 in Review

Mason & Associates (California) reduced its AbbVie (ABBV) stake by 3.2% in Q2 2026, selling an estimated $23.9K and leaving 3,310 shares worth $833K. The position accounts for 0.13% of the portfolio, ranked #85.

Mason & Associates (California) first reported a position in ABBV in Q1 2022 and has held it in 18 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Mason & Associates (California) held 3,310 shares of AbbVie worth $833K as of Q2 2026.
Mason & Associates (California) sold 111 AbbVie shares in Q2 2026, an estimated $23.9K.
AbbVie made up 0.13% of Mason & Associates (California)'s portfolio in Q2 2026, its #85 holding.
Mason & Associates (California) first reported a position in AbbVie in Q1 2022 and has held it in 18 quarters since.
4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Mason & Associates (California)'s 13F filing for Q2 2026, filed 23 Jul 2026.